Enterprise Value

-30.75M

Cash

165.8M

Avg Qtr Burn

-32.49M

Short % of Float

3.23%

Insider Ownership

1.02%

Institutional Own.

54.54%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tamibarotene (SY-1425) (RARα agonist) Details
Cancer, Myelodysplastic syndrome

Big Mover™

Susp. Mover™

Phase 3

Data readout

SM-88 Details
Prostate Cancer

Phase 3

Update

Phase 3

Initiation

Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin Details
Acute myeloid leukemia, Cancer

Big Mover™

Susp. Mover™

Phase 2

Data readout

SM-88 Details
Breast cancer

Phase 2

Data readout

SM-88 Details
Sarcoma, Bone cancer

Phase 2

Update

Failed

Discontinued

Failed

Discontinued

SM-88 Details
Pancreatic cancer

Failed

Discontinued